Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib

Activating mutations in the Kit receptor tyrosine kinase are associated with Gastrointestinal Stromal Tumor (GIST). Imatinib inhibits Kit and is front-line therapy for GIST. However, imatinib most often elicits a partial response or stable disease and most GIST patients who initially respond to imat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rossi, Ferdinand, Yozgat, Yasemin, de Stanchina, Elisa, Veach, Darren, Clarkson, Bayard, Manova, Katia, Giancotti, Filippo, Antonescu, Cristina R., Besmer, Peter
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2952175/
https://ncbi.nlm.nih.gov/pubmed/20736294
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-10-0065
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars